These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37701096)

  • 21. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
    Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
    Kang Y; Ding M; Tian G; Guo H; Wan Y; Yao Z; Li B; Lin D
    Oncol Rep; 2013 Jul; 30(1):313-9. PubMed ID: 23624653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
    Denis I; Cellerin L; Gregoire M; Blanquart C
    Oncotarget; 2014 Nov; 5(22):11641-52. PubMed ID: 25361002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
    Green J; Dundar Y; Dodd S; Dickson R; Walley T
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metallothionein-like proteins and cell resistance to cis-dichlorodiammineplatinum(II) in L1210 cells.
    Farnworth P; Hillcoat B; Roos I
    Cancer Chemother Pharmacol; 1990; 25(6):411-7. PubMed ID: 2311168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.
    Mathilakathu A; Wessolly M; Mairinger E; Uebner H; Kreidt D; Brcic L; Steinborn J; Greimelmaier K; Wohlschlaeger J; Schmid KW; Mairinger FD; Borchert S
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metallothionein 2A induction by zinc protects HEPG2 cells against CYP2E1-dependent toxicity.
    Pérez MJ; Cederbaum AI
    Free Radic Biol Med; 2003 Feb; 34(4):443-55. PubMed ID: 12566070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal and zinc-induced metallothionein in resistance to cadmium, cisplatin, zinc, and tertbutyl hydroperoxide: studies using MT knockout and antisense-downregulated MT in mammalian cells.
    Kennette W; Collins OM; Zalups RK; Koropatnick J
    Toxicol Sci; 2005 Dec; 88(2):602-13. PubMed ID: 16150881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant pleural mesothelioma.
    Chen SE; Pace MB
    Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.